Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A mojo needed as big pharma sales lag drug market growth

This article was originally published in Scrip

Executive Summary

The sales growth of big pharma companies has been lagging behind that of the global drug market since 2011, and the gap is widening. To pull back, M&A is key, but big pharma faces an uphill battle and will need to deploy its resources wisely as its firepower in the deal making marketplace is in decline relative to rival firms in the big biotech and specialty pharma space. These are the conclusions reached by Ernst & Young in a new report entitled Closing the Gap? Big Pharma's Growth Challenge and Implications for Deals.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC019979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel